Object Chronic hepatitis C virus (HCV) infection is commonin hemodialysis (HD) patients. In the present study, the prevalence and properties of HCVin HDpatients were analyzed. Methods and Results Of 125 HDpatients, 34 (27%) were positive for antibody to HCV,and HCV-RNA was detected in 23 (68%) of the 34 patients using reverse transcription polymerase chain reaction. The HCV-RNA sequence analysis did not identify the alterations specific to HDpatients with HCV,although one patient had a variant virus containing the deletion of the core gene sequence. Whenserial changes in the levels of HCV-RNA were evaluated in 15 patients by a branched DNAassay, the values decreased immediately after HDprocedure, but returned to the baseline values 2 days after the procedure. Conclusion These results indicate that HCVin HDpatients is replication-competent, although a transient reduction in the levels of HCV-RNA occurs during HD. (Internal Medicine 38: 626-631, 1999) 
Introduction
Chronic hepatitis C virus (HCV) infection is a commonproblem in patients who receive hemodialysis (HD). In fact, previous studies have demonstrated that as manyas 10 to 40%of HDpatients are chronically infected by HCV,although HCV prevalence in HDpatients is highly variable among different countries and even amongHDunits in the same area (1) (2) (3) . The high prevalence of HCVin HDpatients is believed to be attributed to the transfusion of HCV-contaminated blood products before the availability of reliable HCVscreening. In addition, some investigators have shownthat the length of time on HDis an independent predictor of HCVinfection in chronic HD patients (4, 5) . This finding suggests nosocomial transmission of HCVwithin HDunits.
For editorial comment, see also p 615.
The levels of serum aminotransferases are usually normal or only slightly elevated in HDpatients with HCV (1, 6) . Uremia is considered to predispose a patient to a chronic viral carrier status with little inflammatory activity in the liver. However, recent studies analyzing the liver biopsy samples of HD patients with HCVhave shownthat a large proportion of the patients have apparent chronic liver disease such as chronic active hepatitis and cirrhosis (7, 8) . Moreover, changes in immunestatus caused by immunosuppression after renal transplantation can promote the development of clinically significant inflammatory liver disease.
In the present study, the prevalence rates of antibody to HCV (anti-HCV) and HCV-RNA in 125 patients who received HD for more than 1 year in our hospital were evaluated by a commercially available kit (2nd generation) and by reverse tran-HCVin Hemodialysis Patients phritis (n=79), diabetic nephropathy (n=9), chronic pyelonephritis (n=9), polycystic kidney disease (n=5), lupus nephritis (n=2), amyloidosis (n=l) and unknown etiology (n=20). All patients received HDtreatment for 4-5 hours 3 times a week. The serum levels of alanine aminotransferase (ALT)were regularly measured before each HDprocedure at a 1 month interval. Tests for hepatitis B surface antigen (HBsAg) and antibody to HCV (anti-HCV, 2nd generation) were performed in all patients using commercially available enzyme-linked immunosorbent assay kits (Dainabot and Ortho Diagnostic Systems, respectively). The serum samples immediately before and after HDprocedure and 2 days after the procedure were obtained from each patient with informed consent and stored at -40°C for later analysis of the HCVgenomes.
Qualitative and quantitative analyses of HCV. The serum samples taken immediately before HDprocedure were subjected to analysis for the presence of HCV-RNA by RT-PCR using a commercially available kit (Amplicor, Roche Diagnostic Systems). In patients who were positive for HCV-RNAby RT-PCR, HCVgenotypes were determined by the method described previously by Okamoto et al (9) . The genomic variations in the hypervariable region 1 (HVR1) existing in the putative E2/NS-1 domain and the core region of HCVwere analyzed by using the PCR-single strand conformation polymorphism (PCR-SSCP) assay and direct sequencing, respectively. In the PCR-SSCPassay, the sequence encompassing HVR1was amplified by the nested PCRusing the two sets of primers, external sense primer (nucleotide 1284- product (257 bp in size) was diluted to 1/16 (vol/vol) with a solution containing 98% formamide and 20 mmol// ethylenediaminetetraacetic acid, heat-denatured at 80°C for 5 minutes, chilled on ice, and subjected to electrophoresis in a 10% to 20% density gradient polyacrylamide gel at 300 V for 3 hours at 10°C. The separated bands on the gel were visualized with silver staining. Since heterogenous mixtures of mutant genomesare separated into different bands depending on sequence-specific conformations by this assay, the degree of complexity of HVR1quasispecies was expressed as the number of the bands detected in each patient. Direct sequencing of the core region of HCVlb was performed. Briefly, the two sets of primers based on the published sequence of HCJ4 strain were used: external sense primer (nucleotide 144-167), 5'- The PCR was performed for 40 cycles, in which each cycle included denaturation at 94°C for 1 minute, annealing at 60°C for 1 minute, and primer extension at 72°C for 1 minute. Residual dNTPsand oligonucleotide primers were removed by centrifugation filtration columns (Suprec-02; Takara, Kyoto). Nucleotide sequences were directly determined by the dideoxy chain termination method using the Taq Dye Primer Cycle Sequencing Kit (Applied Biosystems, Ink., Foster, CA) and the Applied Biosystems Model 373A DNASequencing System (Applied Biosystems, Ink.) (12) . The serumlevels of HCV-RNA were measuredby a branched DNA(bDNA) assay (Chiron Corp.). This assay involves the hybridization of synthetic oligonucleotides to the highly conserved 5' noncoding region and the core gene of the HCVRNA (13). The detection limit of this assay was 0.50 x 106 HCV genome equivalents per milliliter (0.5 mEq/ml). When patients had HCV-RNAlevels of 0.5 mEq/ml (a detection limit) or more in the serum samples taken immediately before the HD procedure, the levels of HCV-RNA immediately and 2 days after HDprocedure were also measured by a bDNAassay.
Statistical A nalysis.
Results are expressed as mean±SD. Comparisonswere performed with Student's t test and the chi-square test. All P values were two-tailed, and P values of less than 0.05 were considered to indicate statistical significance.
Results
Prevalence rates of anti-HCV and HCV-RNAin HD patients Of 125 HD patients, 34 (27%) were positive for anti-HCV, and 23 (68%) of these 34 patients were also positive for HCVRNAby RT-PCR. HCV-RNAcould not be detected in any patients whowere negative for anti-HCV (Table 1 ). The mean age and sex ratios were almost similar in anti-HCV-positive and -negative patients. However, the duration of HDin anti-HCV-positive patients was significantly longer than that in anti-HCV-negative patients (p<0.01), while the difference was not significant in HCV-RNA-positive and -negative patients with anti-HCV. Thirty-one (9 1 %) of 34 anti-HCV-positive patients had histories of blood transfusions, as did 55 (60%) of anti-HCV-negative patients (p<0.01). HCV screening in blood donors started in 1989 in Japan. Considering evaluation of the time of blood transfusion in each case, 30 of 31 patients who had histories of blood transfusions and were positive for antiHCVreceived blood transfusions before 1989. The levels of serum ALT were monitored monthly for more than 1 year in all patients. The values were consistently within the normal limit (less than 35 IU//) in a large proportion of the patients irrespective of the positivities of anti-HCV or HCV-RNA.One (3%) of 34 anti-HCV-positive patients and 5 (5%) of 91 anti-HCV-negative patients were positive for HBsAg.In the analysis of the viral genotypes in 23 HCV-RNA-positive patients, 19 (83%) and 3 (13%) had HCVlb and HCV2a, respectively.
Variations of HCVin HDpatients
To investigate the variations of HCVin HD patients, the sequences of HVR1 and the core region of HCVwere analyzed. In 21 of 23 patients who were positive for HCV-RNA, serumsamples were available for analysis of the HVR1 quasispecies by the PCR-SSCPassay. As shown in Fig. 1 , the number of bands separated on the gel corresponding to the degree of the HVR1quasispecies complexity was widely varied, ranging from 1 to 8 (mean, 3.8) in each patient.
The sequence of the HCVcore region could be analyzed in 16 of 19 patients with HCVlb by direct sequencing. In comparison with the amino acid sequence of HCJ4 strain used as a reference sequence, the amino acid substitutions were found mainly in the median portion of the core protein in HDpatients (Fig. 2) . However, the alterations relevant to HDpatients with HCVcould not be identified, although one patient had a variant virus which contained a deletion of the core gene sequence between nucleotide 1 14 and nucleotide 326, resulting in a deletion of the amino acid sequence between the 39th codon 
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and the 110th codon in the core region.
Quantitative analysis of HCVin HDpatients
The serum levels of HCV-RNA were measured by a bDNA assay in 23 patients who were positive for HCV-RNAby RT-PCR. Of 23 patients, 15 (65%) had detectable levels of HCVRNAin sera taken immediately before the HDprocedure, with the values ranging from 0.6 mEq/ml to 50 mEq/ml. Whenserial changes in the levels of HCV-RNA were determined in the 15 patients, the values were found to be significantly reduced immediately after the HDprocedure in a large proportion of patients with HCV,compared with the baseline values (p<0.01 , Fig. 3 ). However,the reduced levels were restored to the baseline values 2 days after the HDprocedure in these patients.
Discussion
Chronic HCVinfection affects approximately 30%of patients on maintenance HD (1-3) . The majority of HDpatients with HCVhave only a minimal derangement in the ALTlevel (1, 6) . However, recent histological analysis of the liver tissue indicates that HDpatients with HCVoften have chronic active hepatitis or cirrhosis (7, 8) . The serum level of vitamin B6 which is indispensable for the measurement ofALTactivity is reduced in HDpatients (14) . This results in relatively low levels of serum ALTin HDpatients despite the presence of progressive liver disease in someof these patients. In addition, the patients with normal liver enzyme levels during HDcan still develop progressive liver disease after renal transplantation (5, 15) . Expression of interleukin-1 (3 and tumor necrosis factor-oc (TNF-a) as well as expression of their inhibitors such as interleukin-1 0 and soluble receptors of TNF-a have been shown to be elevated in HDpatients (16, 17) . Such an imbalance between cytokines and their inhibitors mayplay a pivotal role in the multifaceted process of immune dysfunction in HDpatients. Therefore, characterization of HCVin HDpatients is of importance for the understanding and managementof the virusassociated inflammatory liver disease in these patients.
In the present study, the prevalence rate of anti-HCVin 125 HDpatients was 27%. The rate was higher in patients who received HDfor a relatively longer period, suggesting the risk of nosocomial transmission of HCVwithin the HDunit as reported previously (18, 19) . Taken core gene sequences were also analyzed in this study. The amino acid substitutions were found in each patient. However, no particular substitutions relevant to HDpatients with HCVwere elucidated, although it is noteworthy that one patient had a variant virus containing the deletion of the core gene sequence. The deletion mutant and the full length HCVwould be coinfected in the same hepatocyte and would synthsize viral particles as seen in chronic HBVinfection (24) . Since the HCV core region has several epitopes which play a crucial role in the immuneresponse to HCV (25, 26) , alterations or a deletion in this region in HDpatients can operate on escape from immunepressure, leading to persistence of viral infection. Furthermore, the reduced immunedefense resulting from an imbalance between cytokines and their inhibitors (16, 17) might also be involved in viral persistence in HDpatients.
The time course analysis of the levels of viremia in HDpatients with HCVrepresented a reduction of the levels of HCVRNAimmediately after HD procedure. However, the reduced levels were restored to the baseline values 2 days after the procedure. Similar results were described by Okudaet al, who reported that the levels of HCV-RNA in blood significantly decreased after each HDprocedure (27) . In summary,alterations in the HCVsequence seem to be similar in patients who do and do not receive HD. Although the transient reduction of the levels of HCV-RNA during HD procedure occurs in a large proportion of patients, HCVis replicable in these patients. Worsening of the virus-associated liver inflammation after renal transplantation has often been recognized in HDpatients with HCV (5, 15) . Previous studies have shown that the frequency of HDpatients with HCVwho result in sustained response to interferon is similar to or relatively higher than that of patients who do not receive HD (30, 31) . Taken together, the low pretreatment level of HCV-RNA is an important predictor of response to interferon in patients who do and do not receive HD (30) (31) (32) . Thus, interferon treatment prior to renal transplantation is a possible strategy for the eradication of HCVin HDpatients, particularly in those who have relatively low levels of viremia.
